Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813089 | 0.81 | MAPT (0.45) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL28967824 | 0.80 | SIRT1 (0.50) | CYP1A2ALDH1A1KDM4EMAPTNPSR1 | |
| SCHEMBL8227448 | 0.80 | CYP1A2 (0.43) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL22649169 | 0.80 | CYP1A2 (0.43) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL4950343 | 0.80 | ASAH1 (0.56) | CYP1A2ALDH1A1CES1ASAH1 | |
| SCHEMBL30501189 | 0.79 | SIGMAR1 (0.44) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL27387263 | 0.79 | ASAH1 (0.59) | CYP1A2ALDH1A1CES1ACHEASAH1 | |
| SCHEMBL28876218 | 0.79 | CYP1A2 (0.42) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL8873486 | 0.79 | CYP1A2 (0.48) | CYP1A2ALDH1A1KDM4EMAPTRAB9A | |
| SCHEMBL6520637 | 0.77 | CYP1A2 (0.47) | CYP1A2ALDH1A1KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2073815-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | University of Utah Research Foundation (US) | 2009-07-01 | — | — | EP | disclosed |
| US-7425635-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-09-16 | — | — | US | disclosed |
| WO-2006076337-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20050267172-A1 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-12-01 | — | — | US | disclosed |
| US-6841536-B2 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1493736-A1 | Prodrugs and conjugates of selenol-containing compounds and methods of use thereof | University of Utah Research Foundation (US) | 2005-01-05 | — | — | EP | disclosed |
| US-20030225255-A1 | Use in reducing unwanted side effects of chemo- or radiotherapy of cancer, improving cardiovascular function, preventing mutagenesis, preventing initiation or progression of cancer, reducing toxic consequences of radiation exposure | NATIONAL INSTITUTES OF HEALTH--DIRECTOR DEITR | 2003-12-04 | — | — | US | disclosed |
| EP-1003760-A4 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIV UTAH (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6340746-B1 | THIOLAMINE OR SELENOLAMINE CONJUGATE WITH ANTIOXIDANT VITAMIN; NONTOXIC | UNIVERSITY OF UTAH | 2002-01-22 | — | — | US | disclosed |
| EP-1003760-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | THE UNIVERSITY OF UTAH (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007719-A1 | PRODRUGS AND CONJUGATES OF THIOL- AND SELENOL- CONTAINING COMPOUNDS AND METHODS OF USE THEREOF | UNIVERSITY OF UTAH (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225255-A1 | Use in reducing unwanted side effects of chemo- or radiotherapy of cancer, improving cardiovascular function, preventing mutagenesis, preventing initiation or progression of cancer, reducing toxic consequences of radiation exposure | SCLY, DOHH, GSTO1 | CYP1A2 464/4885ALDH1A1 63/4885KDM4E 3663/4885 |
| US-20050267172-A1 | Prodrugs and conjugates of thiol- and selenol-containing compounds and methods of use thereof | SCLY, SELENOI, GSTO1 | CYP1A2 85/4885ALDH1A1 168/4885KDM4E 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.